PA
ZNTL icon

Profund Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Profund Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,892
Closed -$126K – 1161
2024
Q2 		$126K Sell
30,892
-15,510
-33% -$173K ﹤0.01% 1033
2024
Q1 		$731K Sell
46,402
-11,837
-20% -$163K 0.03% 446
2023
Q4 		$882K Buy
58,239
+24,063
+70% +$351K 0.04% 353
2023
Q3 		$686K Sell
34,176
-11,355
-25% -$288K 0.04% 378
2023
Q2 		$1.28M Buy
45,531
+6,643
+17% +$159K 0.07% 257
2023
Q1 		$669K Buy
+38,888
New +$788K 0.04% 416

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Profund Advisors's ZNTL Position: Q3 2024 in Review

Profund Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 30,892 shares — an estimated $126K sold.

Profund Advisors first reported a position in ZNTL in Q1 2023 and held it in 6 quarters. The position peaked at $1.28M in Q2 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Profund Advisors reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Profund Advisors sold 30,892 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $126K.
  • Profund Advisors first reported a position in Zentalis Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Profund Advisors's Zentalis Pharmaceuticals position peaked at $1.28M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Profund Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.